New Blood Test Shows Promise for Early Cancer Detection and Genetic Insights into Sudden Death
Örebro, Sweden – Researchers at Örebro University Hospital are reporting promising results from a new blood test utilizing Next Generation Sequencing (NGS) technology, perhaps offering earlier cancer detection and improved understanding of genetic factors contributing to sudden death. The study, while currently limited in scope, suggests the test can identify traces of cancer DNA in blood samples, even before symptoms appear.
The research focuses on analyzing circulating tumor DNA (ctDNA) – fragments of DNA released into the bloodstream by cancer cells. By employing NGS,researchers can analyze a vast number of genetic markers together,increasing the sensitivity and accuracy of cancer detection.
“We’ve seen encouraging results in our initial studies, indicating the potential to detect several types of cancer at an earlier stage than current methods allow,” says emma Adolfsson, researcher at Örebro university Hospital. “However, it’s crucial to confirm these findings with a larger number of study participants with cancer to ensure the reliability of the results.”
The potential impact of a widely available, blood-based cancer screening test is significant. it could led to faster diagnoses, less invasive testing procedures, and ultimately, improved survival rates.
Beyond cancer detection, the research also explores the submission of NGS in understanding the genetic causes of sudden death. More accessible and reliable genetic testing could provide families with crucial data for preventative measures.
“Early cancer detection dramatically increases the chances of effective and life-saving treatment. the same holds true for genetic testing related to sudden death, offering families opportunities to prevent future tragedies,” Adolfsson concludes.
Understanding Next Generation Sequencing (NGS)
NGS technology has revolutionized genetic analysis since its introduction around 2005. Its flexibility allows researchers to study numerous genetic aspects simultaneously. While genetic analysis was once prohibitively expensive, NGS has dramatically reduced costs.
Here’s a look at the evolution of genomic sequencing:
* The human Genome Project (1990-2003): An international effort to map the entire human genome took 30 years and cost approximately $1 billion,and even then,it wasn’t a complete sequence.
* NGS Today: The entire human genome can now be analyzed in a single day for around $500 using NGS technology.
* Precision Medicine: NGS is driving the advancement of precision medicine in Swedish healthcare, enabling tailored treatments based on an individual’s genetic makeup.
previously, cancer treatment often involved a one-size-fits-all approach, such as radiation therapy. Now, NGS allows for the sequencing of a tumor’s genetic profile, identifying specific mutations. This information guides the selection of targeted therapies designed to be effective against those particular genetic changes, leading to more personalized and effective cancer care.
Source: Universitetssjukhuset Örebro (https://www.orebrolasarett.se/)
News Source: Örebronyheter (https://www.orebronyheter.se/)